NCT06614140 2026-04-22
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
Seqker Biosciences, Inc.
Phase 1/2 Completed
Clinical Trials
4 trialsNCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT02413827 2017-04-07
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Celldex Therapeutics
Phase 1/2 Terminated
NCT00948961 2016-06-27
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Celldex Therapeutics
Phase 1/2 Completed